(R)-Crizotinib

(R)-Crizotinib

CAT N°: 12087
Price:

From 176.00 149.60

(R)-Crizotinib is a derivative of aminopyridine that acts as a potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases.{22302} (R)-Crizotinib shows antitumor efficacy, including cytoreductive antitumor activity, in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM).{22302,22301} (R)-Crizotinib is currently undergoing active clinical investigation in non-small cell lung cancer and phase I/II studies are being conducted in patients with anaplastic large cell lymphoma or neuroblastoma.{22301,20554}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
  • Correlated keywords
    • 912279-98-2 PF-2341066 PF2341066 02341066 tyrosine RTK ALK anaplastic lymphoma kinases c-MET inhibitors inhibits inhibition hepatocyte growth factors receptors antitumors non-small lungs cancers anaplastic large lymphoma neuroblastoma fusion proteins cMET lower back pains GABAA receptors skeletal muscles relaxant
  • Product Overview:
    (R)-Crizotinib is a derivative of aminopyridine that acts as a potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases.{22302} (R)-Crizotinib shows antitumor efficacy, including cytoreductive antitumor activity, in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM).{22302,22301} (R)-Crizotinib is currently undergoing active clinical investigation in non-small cell lung cancer and phase I/II studies are being conducted in patients with anaplastic large cell lymphoma or neuroblastoma.{22301,20554}

We also advise you